BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Canadian Pulmonary Fibrosis Foundation - ECPv6.17.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://cpff.ca
X-WR-CALDESC:Events for Canadian Pulmonary Fibrosis Foundation
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20230712T140000
DTEND;TZID=America/Toronto:20230712T153000
DTSTAMP:20230608T172126Z
CREATED:20230608T172124Z
LAST-MODIFIED:20230608T172126Z
UID:10000883-1689170400-1689175800@cpff.ca
SUMMARY:FIBRONEER-IPF - A Phase 3 Clinical Trial
DESCRIPTION:Groupe de soutien national virtuel en français\n\n\n\n\n\n\n\n\nBoehringer Ingelheim has enrolled the first patient in FIBRONEER-IPF\, a Phase 3 clinical trial evaluating the efficacy\, safety\, and tolerability of BI 1015550\, an investigational therapy for people with idiopathic pulmonary fibrosis (IPF). \nDonald Zoz\, clinical program leader at Boehringer Ingelheim\, will tell us more about this clinical trial on July 12! \n\n\n\n\n\n\n\n\n\n\nWatch
URL:https://cpff.ca/event/fibroneer-ipf-a-phase-3-clinical-trial/
CATEGORIES:Educational Forums,Featured
ATTACH;FMTTYPE=image/png:https://cpff.ca/wp-content/uploads/2023/06/FIBRONEER-IPF-A-Phase-3-Clinical-Trial-2.png
END:VEVENT
END:VCALENDAR